numares
Private Company
Funding information not available
Overview
Numares AG is a pioneering diagnostics company leveraging a unique combination of NMR spectroscopy and artificial intelligence to analyze blood metabolites. Its core technology, the AXINON® platform, is designed to identify complex disease signatures, moving beyond single biomarkers to enable earlier and more accurate diagnosis of conditions like chronic kidney disease and cardiovascular disorders. As a private company, Numares has progressed key assays through regulatory pathways, positioning itself in the high-growth precision diagnostics market. Its strategy involves both developing its own diagnostic tests and partnering with pharmaceutical companies for companion diagnostics.
Technology Platform
Proprietary high-resolution NMR spectroscopy combined with AI/ML algorithms to analyze metabolic patterns in blood for disease diagnosis and prognosis (AXINON® platform).
Opportunities
Risk Factors
Competitive Landscape
Numares competes in the advanced diagnostics space against large, established players like Roche, Abbott, and Siemens Healthineers, which have broad portfolios and deep commercial reach. It also faces competition from other specialized metabolomics companies using mass spectrometry (e.g., Metabolon) and a growing number of AI-driven diagnostic startups. Its key differentiator is the combination of standardized, quantitative NMR hardware with proprietary AI software in a regulated system.